MannKind Corp. (MNKD)

[Phaeton]

5 Big Biotech Stocks To Buy In 2018

Nice @mannkindcorp mentioned in same article as $CELG $AMGN $LGND $INCY 5 Biotech stocks to buy in 2018

like this guy's #4 Pick...

At least one of these biotech stocks should appeal to every investor.

By Aaron Levitt, InvestorPlace Contributor

https://investorplace.com/2018/01/5-big-biotech-stocks-buy-2018/#.Wl-7qSzrt9A

Looking for the archetype “lotto” ticket biotech stock? Then MannKind Corporation (NASDAQ:MKND) is it.

MannKind has just one product — Afrezza. The drug is an inhalable insulin used to treat diabetes. It could be a miracle cure for those suffering from the disease. Things haven’t turned out well for MKND over the years, however.

Prescriptions for the drug continue to come in well under expectations, and revenues from these written prescriptions have been paltry at best. That’s a problem when you are running low on cash and have some pretty decent debts on your balance sheet.

But there have been some positives lately — like a label ruling update from the FDA and the potential for Afrezza to be covered by insurance for some patients. The hope is that these positives, as well as higher scripts, will happen before MannKind runs out of cash. If and when that does, MKND should pop much higher.

At $2.50 per share, MKND stock is really a lotto ticket. But it may be worth it for investors looking for to add some risk to their portfolios.